3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
3
Phase 1/2
2
Phase 2/3
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
1
CNS
1
Conditions
Neurofibromatosis 1
1
Lymphoma
1
Interventions
pembrolizumab
210
Cyclophosphamide
122
Nivolumab
109
Carboplatin
92
fludarabine
81
Gemcitabine
77
Specimen Handling
74
Bevacizumab
72
venetoclax
70
Injections
70
Magnetic Resonance Spectroscopy
67
Dexamethasone
66
Paclitaxel
64
Biopsy
59
atezolizumab
56
Cisplatin
53
Ipilimumab
50
Temozolomide
45
Docetaxel
42
Azacitidine
42
Pemetrexed
41
Lenalidomide
41
Oxaliplatin
40
Rituximab
39
Radiotherapy
39
Fluorouracil
39
Cetuximab
37
durvalumab
36
Cytarabine
36
Capecitabine
36
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1/2
×
Dosage Forms
×
1 year
×
Clear all
NCT05309668
2025-12-18
SPRINKLE
AstraZeneca
Phase 1/2
Active not recruiting
36 enrolled
37 charts
NCT03593187
2025-11-20
GENHIV
Assistance Publique - Hôpitaux de Paris
Phase 1/2
Completed
2 enrolled